Estrella Immunopharma Stock (NASDAQ:ESLA)

Ownership Financials Chart

Previous Close

$0.85

52W Range

$0.63 - $3.23

50D Avg

$0.92

200D Avg

$1.10

Market Cap

$30.79M

Avg Vol (3M)

$128.18K

Beta

0.24

Div Yield

-

ESLA Company Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

-

IPO Date

Sep 14, 2021

Website

ESLA Performance

ESLA Financial Summary

	Jun 24	Dec 22	Jun 22
Revenue	-	-	-
Operating Income	$-7.31M	$-1.57M	$-1.69M
Net Income	$-7.31M	$-996.10K	$-1.69M
EBITDA	$-7.31M	$-1.57M	$-1.69M
Basic EPS	$-0.27	$-0.17	$-0.29
Diluted EPS	$-0.27	$-0.17	$-0.29

Fiscal year ends in Jun 24 | Currency in USD